A more affordable menopause patch is now available. The FDA has approved the first generic version of Climara Pro, a once-weekly patch delivering estradiol and levonorgestrel to treat moderate-to-severe menopausal symptoms and prevent osteoporosis in postmenopausal women. The move is part of a broader FDA push to expand access to affordable generics amid growing demand and supply shortages for estrogen patches.
The FDA has approved the first generic version of Climara Pro (Bayer), a once-weekly transdermal patch designed to treat moderate-to-severe menopausal symptoms and prevent osteoporosis in postmenopausal women with an intact uterus. The patch delivers a daily dose of 0.045 mg estradiol and 0.015 mg levonorgestrel — a combination that helps reduce the risk of endometrial hyperplasia, a potential complication when estrogen is used alone.
The approval comes at a critical time, as rising demand for hormone therapy has strained estrogen patch supplies nationwide. The FDA had already flagged availability concerns in September and was actively working with manufacturers to boost production. This generic approval is also part of the agency's broader Drug Competition Action Plan, aimed at making medications more affordable and accessible.
Key Takeaways:
Why it matters: With menopause hormone therapy demand surging and supply running thin, this generic approval could meaningfully expand access and reduce out-of-pocket costs for millions of postmenopausal women.
